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Introduction
C T  &  M R I
3D conformal treatment planning in radiation oncology is
based on computed tomography (CT) and magnetic
resonance imaging (MRI). MRI shows the anatomical
structures of soft tissue with a high accuracy. CT is
important for the delineation of bony structures and for
the accurate computation and visualisation of radiation
dose. However, both CT and MRI image the tumour
using differences in the density (that is, intensity of the
signal) of the tissues, the property to enhance contrast
or to accumulate water (oedema). All these signs are
not specific only to tumour tissue. They can also be
observed in changes due to other causes such as surgery,
trauma and vascular disease. This sometimes makes the
tumour diagnosis and delineation difficult and represents
the most important limitation of these CT and MRI
investigations.
P E T  &  S P E C T
Biological imaging visualises biological pathways. Positron
emission tomography [PET] and single photon computed
emission tomography (SPECT) are characterised by the
visualisation of tumours using radioactive tracers with
a higher affinity for tumour when compared to normal
tissue. Basically, we have a biological paradigm where
PET and SPECT can offer additional information about
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The paper presents new techniques of intracranial tumour visualisation – positron emission tomography (PET) and single
photon computed emission tomography (SPECT). In the course of these examinations one may use radiolabelled amino acids,
which are characterized by increased uptake within the tumour. These techniques are very useful for precise 3D radiotherapy
planning, especially in patients with post-surgical residual tumours or in cases when the tumour is located in the direct
vicinity of surrounding skeletal structures, as is the case with meningiomas of the cranial base.
Precise definition of the target is a necessary element of modern radiotherapy, the results of which may be significantly
improved by the use of biological markers in the course of visualization techniques.
Wizualizacja guzów wewnàtrzczaszkowych przy u˝yciu aminokwasów znakowanych izotopami 
a planowanie radioterapii
W pracy przedstawiono techniki wizualizacji guzów wewnàtrzczaszkowych (glejaków i oponiaków) w oparciu o pozytronowà
tomografi´ emisyjnà (PET) i tomografi´ emisyjnà pojedynczego fotonu (SPECT). Podczas tych badaƒ wykorzystuje si´
wi´ksze, w porównaniu ze zdrowà tkankà, powinowactwo guza do niektórych aminokwasów. Znakujàc wybrane aminokwa-
sy izotopowo mo˝na uzyskaç bardzo dok∏adny obraz guza. Techniki te mo˝na wykorzystaç podczas planowania radioterapii,
szczególnie u chorych po operacji, umo˝liwiajà bowiem precyzyjne zaplanowanie dawki w obr´bie pozostawionych frag-
mentów guza. Innà zaletà opisanej metody jest mo˝liwoÊç dok∏adnego okreÊlenia granic guza w sytuacji, gdy znajduje si´ on
w bezpoÊredniej bliskoÊci struktur kostnych. Jest to zw∏aszcza istotne w przypadku oponiaków zlokalizowanych na podstawie
czaszki.
Precyzyjne okreÊlenie granic tkanki nowotworowej jest niezb´dne w nowoczesnej radioterapii, a zastosowanie nieinwazyjnych
technik wizualizacji z wykorzystaniem znaczników biologicznych mo˝e znacznie poprawiç wyniki leczenia.
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tumour extension and biology, when compared to CT or
MRI.
P E T  &  S P E C T  w i t h  a m i n o  a c i d  t r a c e r s
Radiolabelled amino acids are intensively taken up by
glioma cells whereas there is only a low uptake by normal
cerebral tissues. The most important radiolabelled amino
acids used in the diagnosis of gliomas are 11Carbon-
methionine (MET), 123Iodine-alpha-methyl-tyrosine
(IMT) and O-2(18F)fluoroethyl-L-tyrosine (FET).
MET-PET
G l i o m a s
The mechanism and biological significance of increased
11C-MET uptake in gliomas is not yet completely
understood. Planas et al [1] have shown that although
MET is incorporated into proteins, its uptake is probably
not a measure of protein synthesis. The increased uptake
seems to be mainly due to an activation of carrier A- and
L-mediated transport at the blood brain barrier (BBB).
The main advantages of this tracer in neuro-oncology are
given in Table I.
Table I. Main advantages of 11C-MET
– It is very sensitive in delineating various brain tumors including, high
and low grade gliomas, meningiomas, pituitary adenomas and
metastases.
– The transport of across the BBB is mediated by a specific transport
system (L and A type amino acid transporter). Thus a disruption of
the BBB is not required for tumour MET uptake.
– MET uptake is low in the normal white and gray matter.
It is important to mention that low grade gliomas,
especially oligodendrogliomas, show a high MET uptake
in comparison to FDG-PET [2]. Nevertheless, several
studies have demonstrated a correlation between MET
uptake and histological tumour grading [3, 4]. Comparing
CT, MR and MET-PET using stereotactic biopsies,
Mosskin et al [5] and Ogawa et al [3] concluded that
MET-PET has a greater capacity to outline correctly the
true extent of brain gliomas, when compared to CT and
MR. This observation has important consequences for
therapy planning and monitoring of patients with brain
gliomas.
The initial findings regarding the value of MET-PET
and FDG-PET in the follow-up of irradiated patients
with brain gliomas were reported by Würker et al [6].
They analyzed 10 patients with brain gliomas, investigated
with FDG-PET and MET-PET, before and after
brachytherapy with 125I seeds. After one year, glucose
metabolism was not significantly changed whereas MET
uptake showed a significant dose-dependent decrease.
The integration of MET-PET data into treatment
planning systems in radiotherapy has been described by
Julow [7] for brachytherapy but without validation of the
image fusion method. Nuutinen et al [8] have described
the feasibility of MET-PET for radiation treatment
planning of low grade astrocytomas but have used no
image fusion tool.
We introduced MET-PET in the treatment planning
for stereotactic radiotherapy [9] and our study
demonstrated that the automatic image fusion based on
mutual information measured provides a fast and robust
way to reorientate MET-PET and CT data sets.
This first clinical experience reported by our group
[9] showed that MET-PET can improve target volume
definition for stereotactic fractionated radiotherapy of
gliomas. We used the CT/MET-PET images to define the
tumour volume for radiation treatment planning. In
patients with malignant gliomas we delivered 60 Gy in 2
Gy fractions according to 3D traditional treatment
planning and four fractions of 5 Gy using the stereotactic
technique.
The boost volume was defined according to the
MET-PET/CT/MRI fusion images. The gross tumour
volume (GTV) for the stereotactic treatment planning
corresponded to the PTV and represented the MET
uptake. This approach is useful especially for operated
patients. In these cases using CT or MRI, any residual
tumor cannot be differentiated from post-operative BBB
disturbances or from post-operative oedema.
M e n i n g i o m a s
The high affinity of meningiomas for MET has been
described in previous studies [10]. The objective of
stereotactic fractionated radiotherapy is to achieve a high
tumour control with a minimal risk of side effects. The
exact definition of tumour extension is therefore an
important step in stereotactic radiation treatment
planning.
For meningiomas, the GTV is outlined by
considering the contrast enhancement areas in CT and
MRI. Previous studies demonstrated the impact of both
types of investigations in tumour volume definition [11].
However, meningiomas infiltrate the regions of the sella,
cavernous sinus, tentorium, falx cerebri and dura mater
structures. In these regions, characterised by a high
contrast enhancement comparable with the enhancement
of the meningioma itself. Thus using MRI or CT alone it
is impossible to define the tumour infiltration with a high
degree of accuracy.
Difficulties in tumour extension are also known for
surrounding skeletal structures and these have special
implications in orbital, base of skull or clivus meningioma
infiltration. Using MET-PET, tumour borders can be
defined with a higher precision and as a consequence,
critical areas such as optic nerves, pituitary gland,
cavernous sinus including the oculomotorius, the
trochlearis, the abducens and the trigeminus nerves, the
brain stem, and the hypothalamus can be spared from
high radiation dose, Figure 1.
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FET-PET
In preliminary studies it has been demonstrated that
O-2(18F)fluoroethyl-L-tyrosine [FET] shows a similar
uptake in brain tumors as MET. The advantage of the
amino acid analogue FET is that it can be radiolabelled
with 18Fluorine which has a more than five times longer
physical half-life than 11Carbon and can be distributed
to PET centers without the necessity for an onsite
cyclotron.
The aim of our investigation was to compare the
uptake of FET with that of MET in patients with
suspected primary or recurrent intracerebral tumours
[12]. A total of 16 consecutive patients with intracerebral
lesions [high and low grade gliomas and metastases] were
studied on the same day by PET using MET and FET.
Uptake of FET and MET was quantified by standardised
uptake values. Tracer kinetics for normal brain and
intracerebral lesions were compared. On the basis of the
MET-PET studies, viable tumour tissue was found in
13/16 patients.
All tumors showed rapid uptake of FET and were
visualised with high contrast. Mean uptakes of FET for
normal gray matter, white matter and tumour tissue were
respectively 1.1±0.2, 0.8±0.2, and 2.7±0.8 standardised
uptake value [SUV]. In all three tissue types, uptake of
MET was slightly higher (1.4±0.2; 0.9±0.1; 3.3±1.0 SUV;
P<0.01). However, contrast between tumour and normal
tissues was not significantly different between MET and
FET.
Uptake of FET in non-neoplastic lesions [1.0±0.1
SUV] was significantly lower than in tumour tissue,
P=0.007. For all lesions there was a close correlation,
R=0.98, between MET and FET uptake.
In conclusion, in PET studies of human brain
tumours, uptake and image contrast of FET appear to
be very similar to that of MET. The specificity of FET
for tumour tissue is promising but has to be addressed in
a larger series of patients with non-neoplastic lesions.
IMT-SPECT
G l i o m a s
123Iodine-alpha-methyl-tyrosine (IMT) is a synthetic
amino acid whose uptake by gliomas has been shown to
be closely correlated with uptake of 11Carbon-methionine.
In contrast to methionine, IMT can be imaged with the
much more widely available SPECT. It has been
demonstrated in several studies that IMT-SPECT enables
the visualisation of gliomas with high contrast.
Furthermore, IMT-SPECT has been found to be a specific
test for differentiation of tumour recurrence and therapy
induced changes [13-15].
We compared the results of IMT-SPECT with MRI
in tumour volume definition of brain gliomas and
evaluated the influences of the information provided from
IMT-SPECT for 3D conformal treatment planning [16].
In 30 patients with non-resected, histologically proven
brain gliomas (13/30 glioblastoma, 12/30 astrocytoma
grade III, 3/30 astrocytoma grade II, 1/30 oligodendro-
glioma grade III and 1/30 oligodendroglioma grade II).
IMT-SPECT and MRI were performed prior to
treatment in the same week. A special software system
allowed the co-registration of the IMT-SPECT and MRI
data. The GTV defined on the IMT-SPECT/T2-MRI
fusion images (GTV-IMT/T2) was compared with the
GTV-T2 defined on the T2-MRI alone. On the IMT-
SPECT/T1Gd-MRI overlays, the volume of the IMT
tumour uptake (GTV-IMT) was compared with the
volume of the Gadolinium (Gd) enhancement (GTV-
T1Gd).
The initial PTV and the boost volume (BV) outlined
on the IMT-SPECT/T2-MRI co-images were analysed
and compared to the PTV and BV delineated using the
T2-MRI alone. We found a higher IMT uptake of tumour
areas compared to normal brain tissue, in all 30 patients
we studied.
Mean GTV-IMT, mean GTV-T2 and mean GTV-
T1Gd were respectively 43, 82 and 16 cm3. IMT tumour
uptake outside of the contrast enhancement regions was
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Figure 1. Meningioma WHO grade I. CT, MET-PET and CT/MET-PET image fusion [BrainLab system for stereotactic treatment planning].
The tumour is outlined using both investigations. MET-PET helps to define the tumour extension in the region of the sella with a higher accuracy.
Critical organs such as optical nerves, cavernous sinus, cranial nerves can be spared
observed in all patients. Mean relative increase of tumour
volume defined on the fusion images, GTV-IMT/T1Gd
versus GTV-T1Gd alone was 78%. IMT tumour uptake
areas outside of the GTV-T2 were registered in 7/30
patients. In these patients, the mean increase GTV-
IMT/T2 was 33% higher than GTV-T2, defined according
to the T2-MRI data alone.
The additional information provided by
IMT–SPECT modified minimally the initial PTV (mean
relative increase PTV-IMT/T2 versus PTV-T2 of 5%) but
significantly modified the BV (mean relative increase BV-
IMT/T2 versus BV-T2 of 37%).
We concluded that in a significant number of
patients, the IMT-SPECT investigation improves the
tumour detection and delineation in the planning process.
This has important consequences in 3D conformal
treatment planning, especially in the delineation of the
BV, Figure 2.
Po s t - s u r g e r y  g l i o m a s
In 66 post-surgery patients with gliomas who were
scheduled to undergo conformal radiotherapy, IMT-
SPECT images were co-registrated with T1- and T2-
weighted MRI data sets [17]. On these fusion images,
residual tumour volume was delineated using the
combined information of IMT-SPECT and MRI, Table II.
The tumour volume defined on IMT-SPECT was
compared with the volume of contrast enhancement in
T1-weighted MRI studies and the volume defined by the
hyperintensity in T2-weighted images. The regions with
IMT uptake and/or MRI changes (Composite Vol
MRI/IMT), the regions with overlay of IMT uptake and
MRI changes (Common Vol MRI/IMT), the area with
IMT uptake without MRI changes (Increase Vol
MRI/IMT) and the area with only MRI changes (Vol
MRI minus IMT) were separately analyzed.
PTV and BV defined by using the MRI information
alone was compared with PTV-IMT and BV-IMT defined
by additionally using also the SPECT information. Focally
increased IMT uptake was observed in 25/66 patients
whereas contrast enhancement in MRI was outlined in
59/66 patients and hyperintensity area on T2-MRI was
found in all 66 patients.
Mean Composite Vol T2/IMT was 73 cm3. The
Relative Increase Vol T2/IMT, mean Relative Common
Vol T2/IMT and mean Relative Vol T2 minus IMT were
respectively 4%, 6% and 90% of the Composite Vol
T2/IMT.
Mean Composite Vol T1/IMT was 14 cm3 and the
mean Relative Increase Vol T1/IMT, mean Relative
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Figure 2. Glioblastoma T1-MRI with Gadolinium, fusion image T1-MRI/IMT-SPECT and IMT-SPECT
[upper] and T2-MRI, fusion image T2-MRI/IMT-SPECT and IMT-SPECT [lower]. In this case the 
Gd-enhancement region on T1-MRI corresponds to the IMT uptake area on SPECT
Table II. Relationship between IMT uptake on SPECT 
with Gd enhancement and T2-hyperintensity on MRI in 66 patients
with post-surgery gliomas. 
Number of patients with (+) or without (-) IMT uptake, 
Gd enhancement and T2-hyperintensity areas in SPECT and MRI
from the total series of 66 cases: after Grosu et al [17]
Category IMT uptake (+) IMT uptake (-)
Gd enhancement (+) 25 34
Gd enhancement (-) 0 7
T2-hyperintensity (+) 25 41
T2-hyperintensity (-) 0 0
Common Vol T1/IMT and mean Relative Vol T1 minus
IMT were respectively 21%, 4% and 64% of mean
Composite Vol T1/IMT.
In 19/66 patients focal IMT uptake was also located
outside the MRI changes. In this subgroup mean Vol-
IMT, mean Vol T1 and mean Vol T2 were respectively
19 cm3, 10 cm3 and 70 cm3. Mean Relative Increase
T2/IMT was 14% and T1/IMT 61%. In this subgroup the
additional information of SPECT leads to an increase of
BV (mean Relative Increase BV-IMT) of 20%.
We concluded that, in post-surgery patients with
brain gliomas the size and location of residual IMT
uptake differs considerably from abnormalities in post-
operative MRI. Because of the known high specificity of
IMT uptake for tumour tissue, the findings in IMT-
SPECT may significantly modify the PTV for radiation
treatment planning. This helps to focus the high radiation
dose on the tumour volume and to spare normal brain
tissue.
FDG-PET
One of the most widely used functional investigations in
the diagnosis of brain gliomas is 18F-fluorodeoxiglucose
(FDG)-PET. The rationale for the application of the
glucose analogue FDG in the study of brain gliomas, is
the known increased glucose metabolism in malignant
tumour tissue. Almost 80 years ago, Otto Warburg [18]
postulated that the rate of anaerobic glycolysis is positively
correlated with the degree of tumour cell malignancy.
Consequently is a high glucose utilisation rate and an
increased utilisation of the glucose-6-phosphate inter-
mediate will be observed.
FDG is transported across the BBB by the same
carrier molecules as glucose, so that disturbance of the
BBB is not necessary for FDG accumulation. Hexokinase
transforms the FDG in FDG-6P and this then accumu-
lates in tissue [19].
Clinical studies have demonstrated that the FDG
uptake in tumour tissue is correlated with histological
grading and has prognostic implications. Goldman et al
[20] analysed 160 biopsies taken from 20 patients with
low and high grade gliomas and compared the results
with the FDG uptake in PET. They demonstrated that
the FDG uptake in gliomas is anatomically heterogeneous
and is regionally related to the presence of anaplasia.
An important finding for clinical practice is that
FDG-PET investigations can be successfully used in the
diagnosis of necrosis after radiotherapy or local admi-
nistrated chemotherapy, and also in the differentiation
of necrotic tissue from recurrence.
Gross et al [21] assessed the value of FDG-PET for
3D treatment planning in 18 patients with malignant brain
gliomas. Using PET/MR fusion images, the tumour
volume in PET was compared with tumour volume in
MRI. This study showed that the difference in contrast
between viable tumour and normal brain tissue in FDG-
PET is small. The FDG uptake in gray matter is high,
and this makes the demarcation of the tumour borders
from normal brain tissue difficult.
Nevertheless, tumour areas with lower cellular
differentiation showed higher FDG uptake. An
interesting finding in this study was that tumour areas
with higher FDG-uptake were closely correlated with the
Gd-enhancement areas in MR. Although FDG-PET
offers in comparison to MR, no additional data con-
cerning tumour extension, it could be used to define areas
with higher anaplasia. This raises questions regarding the
possible significance of this investigation in the definition
of a target in target, which could be potentially useful in
dose escalation studies.
Other biological investigation methods
Sophisticated techniques such as MR spectroscopy
showed tumour signs extending outside the MRI derived
PTV. In a recent study Pirzkall et al [22] compared MR
spectroscopy and MRI in patients with high grade gliomas
prior to surgery. These authors demonstrated that,
although T2-MRI estimated the region at risk of
microscopic disease as being as much as 50% greater
than by MR spectroscopy, metabolically active tumour
still extended outside the T2 region in 88% of patients by
as much as 28 mm.
T1-MRI showed a lesser volume and different
location of active disease compared to MR spectroscopy.
Furthermore, in a retrospective analysis of patients with
recurrent brain gliomas treated with Gamma Knife
radiosurgery based on MRI-T1, Graves et al [23] showed
that the outcome of patients with tumour infiltration in
MR spectroscopy located outside of the changes in
conventional MRI was significantly worse than in patients
without additional information in MR spectroscopy
concerning tumour extension.
201Thallium is taken up by the sodium/potassium
symporter of viable cells. SPECT imaging with 201Th has
been used for several years for the differential diagnosis
of radiation necrosis and tumour recurrence [24].
However, 201Tl does not cross the BBB. Therefore, it is
not possible to delineate tumour cell infiltration that has
not caused a disturbance of the BBB.
Finally, brain tumours have been imaged in
preliminary studies by 99mTechnetium-sestamibi which is
a lipophilic cation whose cellular uptake is dependent on
tissue perfusion and the mitochondrial membrane
potential [24]. However, similarly to 201Tl, 99mTc-sestamibi
does not cross the BBB and is therefore limited in its use
for delineation of tumour cell infiltration.
Conclusions
Stereotactic radiotherapy, radiosurgery and intensity
modulated radiotherapy (IMRT) are characterised by the
application of the radiation with high precision of an
exactly defined target and by a very rapid fall-off of dose
to spare normal tissue. The first requirement for the
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success of this therapy is the correct definition of tumor
extension.
Non-invasive imaging techniques are a central
component of treatment planning in radiation oncology.
The information gained from different imaging modalities
is usually of a complementary nature, Table III.
Table III. Useful information from different imaging modalities
Modality Information
MR Describes the anatomical structures of soft tissue
with a high accuracy.
CT Important for the delineation of bone structures and
for the accurate computation of radiation dose.
PET & SPECT Offer additional information about tumor extension
and biology.
Thus, the definition of tumour extension is
characterised by a proper integration of different imaging
modality information. Combining morphological (CT,
MRI) with biological imaging data (PET, SPECT, MR-
Spectroscopy) significantly improves the possibilities for
the physician to interpret 3D brain data.
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